{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:04:34Z","timestamp":1793210674738,"version":"4.5.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Obesity contributes to chronic inflammation and estrogen dysregulation, mechanisms linked to increased breast cancer (BC) risk and recurrence, particularly in postmenopausal women. Bariatric surgery and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective weight-loss interventions, but their comparative impact on BC outcomes remains unclear. This study compared long-term overall survival (OS) and locoregional recurrence (LRR) among postmenopausal BC patients with obesity treated with GLP-1RAs, bariatric surgery, or both.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Using the TriNetX Network, a real-world federated research database of de-identified electronic records from multiple health care organizations, we identified women aged \u226550 years with BMI \u226530\u00a0kg\/m\u00b2 and stage 0\u2013III BC. Study 1 compared patients who initiated GLP-1RA therapy \u22656 months after BC diagnosis with those who underwent bariatric surgery during the same interval. Study 2 compared patients who received both bariatric surgery and GLP-1RA therapy with those who underwent surgery alone. Propensity score matching (1:1) was performed for age, BMI, tumor stage, receptor status, adjuvant therapy, other cancers, and comorbidities. Outcomes included OS and LRR, assessed from 30 days to 10 years after the index event (bariatric surgery or GLP-1RA initiation). Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In Study 1, 22,532 GLP-1RA users and 3468 bariatric surgery patients were identified; 3438 were matched in each cohort. 10-year OS was similar (87% vs. 83%), yet GLP-1RA users experienced significantly lower instantaneous mortality risk (HR 0.57, 95% CI: 0.45\u20130.73), indicating fewer or delayed deaths over time. LRR occurred in 1.8% vs. 4.7% (HR 0.52, 95% CI: 0.39\u20130.70), also favoring GLP-1RA therapy.<\/jats:p>\n                    <jats:p>In Study 2, 1220 patients underwent both bariatric surgery and GLP-1RA therapy and 3468 underwent surgery alone; 1129 were matched per group. The combination group showed higher OS (91% vs. 80%; HR 0.44, 95% CI: 0.29\u20130.67) and lower LRR (2.5% vs. 5.8%; HR 0.52, 95% CI: 0.33\u20130.81).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Among postmenopausal women with obesity and stage 0\u2013III BC, GLP-1RA therapy was associated with improved OS and lower LRR compared with bariatric surgery alone. Combination therapy achieved the most favorable oncologic outcomes, suggesting a potential synergistic effect. The advantage observed with GLP-1RAs may reflect oncologic effects beyond weight loss, potentially through anti-inflammatory, insulin-modulating, or other metabolic pathways. These findings support further investigation into the underlying biological mechanisms and potential role of GLP-1RAs in oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/sla.0000000000007121","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:00:22Z","timestamp":1781582422000},"page":"534-545","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["GLP-1 Receptor Agonists versus Bariatric Surgery in Breast Cancer"],"prefix":"10.1097","volume":"284","author":[{"given":"Jennifer","family":"Den","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Vaghjiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Suzanne","family":"Klimberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"R1-20260919","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s13679-023-00527-y","article-title":"Update on the obesity epidemic: after the sudden rise, is the upward trajectory beginning to flatten?","volume":"12","author":"Koliaki","year":"2023","journal-title":"Curr Obes Rep"},{"key":"R2-20260919","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.15585\/mmwr.mm6639e1","article-title":"Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity\u2014United States, 2005\u20132014","volume":"66","author":"Steele","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R3-20260919","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body Fatness and Cance\u2014Viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"key":"R4-20260919","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.soard.2023.01.025","article-title":"Excess body fatness and cancer risk: a summary of the epidemiologic evidence","volume":"19","author":"Patel","year":"2023","journal-title":"Surg Obes Relat Dis Off J Am Soc Bariatr Surg"},{"key":"R5-20260919","doi-asserted-by":"crossref","first-page":"705911","DOI":"10.3389\/fonc.2021.705911","article-title":"Obesity and breast cancer: a paradoxical and controversial relationship influenced by menopausal status","volume":"11","author":"Garc\u00eda-Est\u00e9vez","year":"2021","journal-title":"Front Oncol"},{"key":"R6-20260919","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10147-014-0712-4","article-title":"Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index","volume":"20","author":"Santa-Maria","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"R7-20260919","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11864-015-0341-9","article-title":"Obesity and breast cancer: not only a risk factor of the disease","volume":"16","author":"Chan","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"R8-20260919","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mce.2017.09.014","article-title":"Obesity and breast cancer\u2014role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue","volume":"466","author":"G\u00e9rard","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"R9-20260919","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.2009.27.2021","article-title":"Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial","volume":"28","author":"Sestak","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"R10-20260919","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jamaoncol.2015.1546","article-title":"Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the Women\u2019s Health Initiative Randomized Clinical Trials","volume":"1","author":"Neuhouser","year":"2015","journal-title":"JAMA Oncol"},{"key":"R11-20260919","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.breast.2016.05.013","article-title":"Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients","volume":"32","author":"Karatas","year":"2017","journal-title":"Breast"},{"key":"R12-20260919","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-022-06664-7","article-title":"Postmenopausal overweight and breast cancer risk; results from the KARMA cohort","volume":"196","author":"Klintman","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"R13-20260919","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/oby.23464","article-title":"Weight-change trajectory in relation to cancer risk: findings from a nationwide cohort study in South Korea","volume":"30","author":"Tran","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"R14-20260919","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1467-789X.2012.01010.x","article-title":"A systematic review of the impact of weight loss on cancer incidence and mortality","volume":"13","author":"Birks","year":"2012","journal-title":"Obes Rev"},{"issue":"suppl 2","key":"R15-20260919","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.breast.2013.07.006","article-title":"Nutrition and physical activity influence on breast cancer incidence and outcome","volume":"22","author":"Chlebowski","year":"2013","journal-title":"Breast"},{"key":"R16-20260919","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/jnci\/djz226","article-title":"Sustained weight loss and risk of breast cancer in women 50 years and older: a pooled analysis of prospective data","volume":"112","author":"Teras","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"R17-20260919","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/cncr.31687","article-title":"Weight loss and breast cancer incidence in postmenopausal women","volume":"125","author":"Chlebowski","year":"2019","journal-title":"Cancer"},{"key":"R18-20260919","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.18632\/oncotarget.26864","article-title":"Weight loss, diet composition and breast cancer incidence and outcome in postmenopausal women","volume":"10","author":"Pan","year":"2019","journal-title":"Oncotarget"},{"key":"R19-20260919","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R20-20260919","doi-asserted-by":"crossref","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R21-20260919","doi-asserted-by":"crossref","first-page":"e5826","DOI":"10.1590\/1414-431x20165826","article-title":"Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages","volume":"49","author":"Guo","year":"2016","journal-title":"Braz J Med Biol Res"},{"key":"R22-20260919","doi-asserted-by":"crossref","first-page":"20420188231222370","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R23-20260919","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1530\/EC-19-0467","article-title":"The metabolic benefits of different bariatric operations: what procedure to choose?","volume":"9","author":"Sudlow","year":"2020","journal-title":"Endocr Connect"},{"key":"R24-20260919","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1470-2045(09)70159-7","article-title":"Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial","volume":"10","author":"Sj\u00f6str\u00f6m","year":"2009","journal-title":"Lancet Oncol"},{"key":"R25-20260919","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1001\/jama.2022.9009","article-title":"Association of bariatric surgery with cancer risk and mortality in adults with obesity","volume":"327","author":"Aminian","year":"2022","journal-title":"JAMA"},{"key":"R26-20260919","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/aje\/153.9.865","article-title":"Factors associated with age at natural menopause in a multiethnic sample of midlife women","volume":"153","author":"Gold","year":"2001","journal-title":"Am J Epidemiol"},{"key":"R27-20260919","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1097\/MLR.0b013e318277eb6f","article-title":"Validating billing\/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts","volume":"52","author":"Hassett","year":"2014","journal-title":"Med Care"},{"key":"R28-20260919","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fonc.2016.00018","article-title":"Validation of claims algorithms for progression to metastatic cancer in patients with breast, non-small cell lung, and colorectal cancer","volume":"6","author":"Nordstrom","year":"2016","journal-title":"Front Oncol"},{"key":"R29-20260919","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canep.2019.01.016","article-title":"A validated algorithm for register-based identification of patients with recurrence of breast cancer\u2014based on Danish Breast Cancer Group (DBCG) data","volume":"59","author":"Aagaard Rasmussen","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"R30-20260919","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","article-title":"Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance","volume":"17","author":"Nguyen","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"R31-20260919","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/SLA.0000000000002525","article-title":"Bariatric surgery and the risk of cancer in a large multisite cohort","volume":"269","author":"Schauer","year":"2019","journal-title":"Ann Surg"},{"key":"R32-20260919","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/oby.23563","article-title":"Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: a systematic review and meta-analysis","volume":"30","author":"Sarma","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"R33-20260919","first-page":"e71684","article-title":"Comparative effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists on cardiovascular outcomes and mortality: a meta-analysis","volume":"16","author":"Saeed","year":"2024","journal-title":"Cureus"},{"key":"R34-20260919","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jama.2017.20513","article-title":"Association of Bariatric Surgery Using Laparoscopic Banding, Roux-en-Y Gastric Bypass, or Laparoscopic Sleeve Gastrectomy vs Usual Care Obesity Management With All-Cause Mortality","volume":"319","author":"Reges","year":"2018","journal-title":"JAMA"},{"key":"R35-20260919","doi-asserted-by":"crossref","first-page":"e2415392","DOI":"10.1001\/jamanetworkopen.2024.15392","article-title":"Bariatric metabolic surgery vs glucagon-like peptide-1 receptor agonists and mortality","volume":"7","author":"Dicker","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R36-20260919","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and risks of bariatric surgery in adults: a review","volume":"324","author":"Arterburn","year":"2020","journal-title":"JAMA"},{"key":"R37-20260919","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s10555-024-10192-9","article-title":"The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer","volume":"43","author":"Ibrahim","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"R38-20260919","doi-asserted-by":"crossref","first-page":"E1431","DOI":"10.1152\/ajpendo.00017.2014","article-title":"Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner","volume":"306","author":"Zhao","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R39-20260919","doi-asserted-by":"crossref","first-page":"e24604","DOI":"10.1002\/jcla.24604","article-title":"GLP1R inhibits the progression of endometrial carcinoma through activation of cAMP\/PKA pathway","volume":"36","author":"Li","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"R40-20260919","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.3390\/ijerph17155445","article-title":"Inflammatory biomarkers and breast cancer risk: a systematic review of the evidence and future potential for intervention research","volume":"17","author":"Kehm","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"R41-20260919","first-page":"2261","article-title":"Correlation of the pro-inflammatory cytokines IL-1\u03b2, IL-6, and TNF-\u03b1, inflammatory markers, and tumor markers with the diagnosis and prognosis of colorectal cancer","volume":"13","author":"Florescu","year":"2023","journal-title":"Life (Basel, Switzerland)"},{"key":"R42-20260919","doi-asserted-by":"crossref","first-page":"103213","DOI":"10.1016\/j.eclinm.2025.103213","article-title":"Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study","volume":"83","author":"Wolff Sagy","year":"2025","journal-title":"eClinicalMedicine"},{"key":"R43-20260919","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/clinem\/dgaf053","article-title":"Semaglutide reprograms macrophages via the GLP-1R\/PPARG\/ACSL1 pathway to suppress papillary thyroid carcinoma growth","volume":"110","author":"Wang","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"R44-20260919","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s44324-025-00054-5","article-title":"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression","volume":"3","author":"Marathe","year":"2025","journal-title":"NPJ Metab Heal Dis"},{"key":"R45-20260919","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13046-024-03263-w","article-title":"The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration","volume":"44","author":"Cencioni","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"R46-20260919","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3390\/biom15030408","article-title":"Weight reduction with GLP-1 agonists and paths for discontinuation while maintaining weight loss","volume":"15","author":"Reiss","year":"2025","journal-title":"Biomolecules"},{"key":"R47-20260919","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s12916-025-04200-0","article-title":"Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications","volume":"23","author":"Wu","year":"2025","journal-title":"BMC Med"},{"key":"R48-20260919","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00423-025-03831-4","article-title":"GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis","volume":"410","author":"Tan","year":"2025","journal-title":"Langenbeck\u2019s Arch Surg"},{"key":"R49-20260919","doi-asserted-by":"crossref","first-page":"e13811","DOI":"10.1111\/obr.13811","article-title":"Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: a systematic review and meta-analysis","volume":"25","author":"Esparham","year":"2024","journal-title":"Obes Rev an Off J Int Assoc Study Obes"},{"key":"R50-20260919","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s11695-025-07723-w","article-title":"The efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists for insufficient weight loss or regain after metabolic\/bariatric surgery: a systematic review and meta-analysis","volume":"35","author":"Kellett","year":"2025","journal-title":"Obes Surg"},{"key":"R51-20260919","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s40519-025-01770-z","article-title":"The role of glucagon-like peptide-1 receptor agonists in weight regain treatment or prevention after bariatric surgery: a systematic review and meta-analysis","volume":"30","author":"Mousavi","year":"2025","journal-title":"Eat Weight Disord"},{"key":"R52-20260919","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12902-025-01913-4","article-title":"Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study","volume":"25","author":"Jensen","year":"2025","journal-title":"BMC Endocr Disord"}],"container-title":["Annals of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/SLA.0000000000007121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:05:23Z","timestamp":1789779923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/SLA.0000000000007121"}},"subtitle":["A Comparative Study of Oncologic Outcomes"],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/sla.0000000000007121","relation":{},"ISSN":["0003-4932","1528-1140"],"issn-type":[{"value":"0003-4932","type":"print"},{"value":"1528-1140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"2026-04-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}